Guggenheim downgraded shares of TESARO (NASDAQ:TSRO) from a buy rating to a neutral rating in a report published on Monday, Marketbeat.com reports. Guggenheim currently has $75.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $69.00.

A number of other equities analysts also recently issued reports on TSRO. Robert W. Baird set a $75.00 price objective on TESARO and gave the stock a hold rating in a report on Monday. HC Wainwright reiterated a buy rating and issued a $69.00 price objective on shares of TESARO in a report on Monday. SunTrust Banks downgraded TESARO from a buy rating to a hold rating and increased their price objective for the stock from $65.00 to $75.00 in a report on Monday. Wells Fargo & Co downgraded TESARO from an outperform rating to a market perform rating in a report on Monday. Finally, BidaskClub upgraded TESARO from a buy rating to a strong-buy rating in a report on Friday, October 19th. Fifteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $78.18.

Shares of TSRO stock opened at $73.78 on Monday. TESARO has a 52 week low of $23.41 and a 52 week high of $85.48. The firm has a market capitalization of $4.06 billion, a P/E ratio of -8.05 and a beta of 1.49. The company has a quick ratio of 2.83, a current ratio of 3.40 and a debt-to-equity ratio of 3.74.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.62) by $0.13. The business had revenue of $64.40 million during the quarter, compared to the consensus estimate of $71.84 million. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The firm’s quarterly revenue was down 54.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.47) earnings per share. Sell-side analysts anticipate that TESARO will post -10.92 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of TESARO by 1.5% during the third quarter. BlackRock Inc. now owns 4,285,890 shares of the biopharmaceutical company’s stock valued at $167,194,000 after acquiring an additional 64,579 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of TESARO by 3.6% during the third quarter. Vanguard Group Inc. now owns 3,336,421 shares of the biopharmaceutical company’s stock valued at $130,154,000 after acquiring an additional 116,337 shares in the last quarter. Frontier Capital Management Co. LLC increased its holdings in shares of TESARO by 77.9% during the third quarter. Frontier Capital Management Co. LLC now owns 3,139,778 shares of the biopharmaceutical company’s stock valued at $122,483,000 after acquiring an additional 1,375,361 shares in the last quarter. BB Biotech AG increased its holdings in shares of TESARO by 20.8% during the third quarter. BB Biotech AG now owns 2,931,802 shares of the biopharmaceutical company’s stock valued at $114,370,000 after acquiring an additional 505,000 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of TESARO by 27.8% during the third quarter. TIAA CREF Investment Management LLC now owns 1,372,970 shares of the biopharmaceutical company’s stock valued at $53,560,000 after acquiring an additional 298,457 shares in the last quarter.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: How to interpret a stock’s beta number

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.